User profiles for MATTHEOS BOBOS
Mattheos BobosSurgical Pathologist Verified email at ihu.gr Cited by 3723 |
Histopathologic classification and prognostic factors of melanoma: a 2021 update.
M Bobos - Italian journal of dermatology and venereology, 2021 - europepmc.org
Despite the rapid recent advances in molecular analysis of tumors, which allow large-scale
and high-resolution genomics, the" gold standard" for melanoma diagnosis continues to be …
and high-resolution genomics, the" gold standard" for melanoma diagnosis continues to be …
Immunohistochemical distinction between Merkel cell carcinoma and small cell carcinoma of the lung
M Bobos, P Hytiroglou, I Kostopoulos… - The American Journal …, 2006 - journals.lww.com
We assessed the usefulness of several immunohistochemical stains in distinguishing these
two neoplasms, including cytokeratin 7, cytokeratin 20 (CK20), neuron-specific enolase, …
two neoplasms, including cytokeratin 7, cytokeratin 20 (CK20), neuron-specific enolase, …
Challenges in sarcoidosis and sarcoid‐like reactions associated to immune checkpoint inhibitors: a narrative review apropos of a case
…, C Kemanetzi, C Papageorgiou, M Bobos… - Dermatologic …, 2021 - Wiley Online Library
Sarcoidosis and sarcoid‐like reactions (SLRs) may develop in association with various
malignancies, as well as in association to certain oncologic drugs, including immune checkpoint …
malignancies, as well as in association to certain oncologic drugs, including immune checkpoint …
Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative …
…, S Glentis, E Bournakis, M Bobos… - Breast cancer research …, 2012 - Springer
In spite the close association of the triple-negative breast cancer immunophenotype with
hereditary breast cancers and the BRCA1 pathway, there is a lack of population studies that …
hereditary breast cancers and the BRCA1 pathway, there is a lack of population studies that …
[HTML][HTML] Tumors with high-density tumor infiltrating lymphocytes constitute a favorable entity in breast cancer: a pooled analysis of four prospective adjuvant trials
Background Tumor infiltrating lymphocytes (TILs) are considered in the prognosis of breast
cancer (BC) patients. Here, we investigated the prognostic/predictive effect of TILs in patients …
cancer (BC) patients. Here, we investigated the prognostic/predictive effect of TILs in patients …
[HTML][HTML] Potential value of PTEN in predicting cetuximab response in colorectal cancer: an exploratory study
…, I Kostopoulos, E Samantas, I Xanthakis, M Bobos… - BMC cancer, 2008 - Springer
Background The epidermal growth factor receptor (EGFR) is over-expressed in 70–75% of
colorectal adenocarcinomas (CRC). The anti-EGFR monoclonal antibody cetuximab has …
colorectal adenocarcinomas (CRC). The anti-EGFR monoclonal antibody cetuximab has …
Gemcitabine combined with gefitinib in patients with inoperable or metastatic pancreatic cancer: a phase II Study of the Hellenic Cooperative Oncology Group with …
G Fountzilas, M Bobos, A Kalogera-Fountzila… - Cancer …, 2008 - Taylor & Francis
The combination of gemcitabine and gefitinib was evaluated in advanced pancreatic cancer.
Totally, 53 patients were treated with a 7 week cycle of gemcitabine (1,000 mg/m 2 given …
Totally, 53 patients were treated with a 7 week cycle of gemcitabine (1,000 mg/m 2 given …
[HTML][HTML] Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel
Background The aim of the present study was to investigate the efficacy of adjuvant dose-dense
sequential chemotherapy with epirubicin, paclitaxel, and CMF in subgroups of patients …
sequential chemotherapy with epirubicin, paclitaxel, and CMF in subgroups of patients …
Second primary melanomas in a cohort of 977 melanoma patients within the first 5 years of monitoring
…, C Papageorgiou, I Boukovinas, M Bobos… - Journal of the American …, 2020 - Elsevier
Background In retrospective studies, a second primary melanoma (SPM) develops in 2%-20%
of melanoma patients. Scarce evidence exists on the usefulness of total-body …
of melanoma patients. Scarce evidence exists on the usefulness of total-body …
[HTML][HTML] Prognostic implications of mismatch repair deficiency in patients with nonmetastatic colorectal and endometrial cancer
Background The clinical relevance of mismatch repair (MMR) status in patients with
nonmetastatic cancer across tumour types remains unclear. Our goal was to investigate the …
nonmetastatic cancer across tumour types remains unclear. Our goal was to investigate the …